Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Mar 2:5:9.
doi: 10.1186/1749-8090-5-9.

Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction

Affiliations
Case Reports

Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction

Georgios Papadopoulos et al. J Cardiothorac Surg. .

Abstract

This the case of a 63 year-old man with end-stage renal disease (on chronic hemodialysis), unstable angina and significantly impaired myocardial contractility with low left ventricular ejection fraction, who underwent off-pump one vessel coronary bypass surgery. Combined continuous levosimendan and norepinephrine infusion (at 0.07 microg/kg/min and 0.05 microg/kg/min respectively) started immediately after anesthesia induction and continued for 24 hours. The levosimendan/norepinephrine combination helped maintain an appropriate hemodynamic profile, thereby contributing to uneventful completion of surgery and postoperative hemodynamic stability. Although levosimendan is considered contraindicated in ESRD patients, this case report suggests that combined perioperative levosimendan/norepinephrine administration can be useful in carefully selected hemodialysis patients with impaired myocardial contractility and ongoing myocardial ischemia, who undergo off-pump myocardial revascularization surgery.

PubMed Disclaimer

Similar articles

Cited by

  • Levosimendan in critical illness: a literature review.
    Pierrakos C, Velissaris D, Franchi F, Muzzi L, Karanikolas M, Scolletta S. Pierrakos C, et al. J Clin Med Res. 2014 Apr;6(2):75-85. doi: 10.14740/jocmr1702w. Epub 2014 Feb 6. J Clin Med Res. 2014. PMID: 24578748 Free PMC article. Review.

References

    1. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996;279:120–127. - PubMed
    1. Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpelainen I, Haikala H. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol. 2000;32:479–491. doi: 10.1006/jmcc.1999.1093. - DOI - PubMed
    1. Simdax - Levosimendan 2.5 mg/mL injection concentrate - Data Sheet. New Zealand, New Zealand Medicines and Medical Devices Safety Authority, a Business Unit of the Ministry of Health; 2009. http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm 1-10-2010.
    1. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–1891. doi: 10.1001/jama.297.17.1883. - DOI - PubMed
    1. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999;288:316–325. - PubMed

Publication types

MeSH terms